ARTICLE | Company News

Actient, UCB sales and marketing update

August 2, 2010 7:00 AM UTC

UCB granted Actient rights to market six products in the U.S. UCB will receive an upfront payment and is eligible for royalties. Actient has an option to purchase the products, which are all marketed in the U.S. UCB said the products covered by the deal had gross sales of $53 million in 2009 and include Edex alprostadil for erectile dysfunction, Theo-24 theophylline for asthma, allergy drug Semprex-D acrivastine/pseudoephedrine, Levatol penbutolol for hypertension, musculoskeletal drug Robaxin methocarbamol and Dilatrate-SR isosorbide to prevent angina pectoris due to coronary artery disease (CAD). Further terms were not disclosed. ...